Edesa Biotech (NASDAQ:EDSA - Get Free Report) is expected to be posting its results after the market closes on Monday, August 10th. Analysts expect the company to announce earnings of ($0.4350) per share for the quarter.
Edesa Biotech (NASDAQ:EDSA - Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.25). On average, analysts expect Edesa Biotech to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Edesa Biotech Price Performance
NASDAQ EDSA opened at $5.27 on Friday. Edesa Biotech has a 1-year low of $0.72 and a 1-year high of $20.32. The firm has a market capitalization of $50.77 million, a P/E ratio of -3.93 and a beta of 1.08. The business's 50-day simple moving average is $6.41 and its 200-day simple moving average is $6.23.
Institutional Investors Weigh In On Edesa Biotech
Several institutional investors and hedge funds have recently modified their holdings of the stock. DRW Securities LLC acquired a new position in Edesa Biotech during the 4th quarter worth approximately $191,000. Diadema Partners LP acquired a new stake in Edesa Biotech in the fourth quarter valued at approximately $77,000. State Street Corp acquired a new stake in Edesa Biotech in the fourth quarter valued at approximately $27,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Edesa Biotech during the third quarter valued at approximately $36,000. Hedge funds and other institutional investors own 5.50% of the company's stock.
Analysts Set New Price Targets
Several research analysts recently commented on EDSA shares. Wall Street Zen lowered shares of Edesa Biotech from a "sell" rating to a "strong sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Edesa Biotech in a research note on Wednesday, June 24th. Finally, Brookline Capital Markets raised shares of Edesa Biotech to a "strong-buy" rating in a research report on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.
Get Our Latest Stock Analysis on Edesa Biotech
About Edesa Biotech
(
Get Free Report)
Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa's approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.
Among Edesa's pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Edesa Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edesa Biotech wasn't on the list.
While Edesa Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
